Uric Acid and Hypertension in African Americans

PHASE3CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

May 31, 2011

Study Completion Date

May 31, 2011

Conditions
Cardiovascular DiseasesHeart DiseasesHypertension
Interventions
DRUG

Allopurinol

Allopurinol (300 mg capsule) was given for 8-10 weeks compared to placebo group after initial baseline testing. After two weeks on the Allopurinol, a serum uric acid level was obtained. If the uric acid level was greater than 5.5, the Allopurinol dosage was increased to 600mg (two 300 mg capsules)for the duration of the trial, 6-8 weeks.

DRUG

Placebo

Placebo capsule (matched in appearance for Allopurinol and labeled 300mg) was given for 8-10 weeks compared to the Allopurinol group after initial baseline testing. After two weeks on the placebo, a serum uric acid level was obtained. If the uric acid level was greater than 5.5, the placebo dosage was increased to 600mg (two 300 mg capsules)for the duration of the study, 6-8 weeks.

DRUG

Chlorthalidone

Chlorthalidone 25 mg was given daily for 5 weeks before baseline visit for testing and continued through out the study.

DRUG

Potassium chloride

Potassium Chloride 40-50meq was given daily for 5 weeks before baseline visit for testing and continued through out the study.

Trial Locations (1)

32610

University of Florida, Gainesville

All Listed Sponsors
lead

University of Florida

OTHER

NCT00241839 - Uric Acid and Hypertension in African Americans | Biotech Hunter | Biotech Hunter